Roth Capital affirms its Buy/Focus Pick rating and $25 price target on TG Therapeutics (Nasdaq: TGTX) following news that the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE